血清胸苷激酶1在恶性肿瘤患者化疗前后检测的意义

Significance of Detecting Serum Thymidine Kinase-1 in the Malignant Tumor Before and After Chemotherapy

目的探讨恶性肿瘤患者化疗前后血清胸苷激酶1(S-TK1)水平变化的临床意义。方法入组经病理证实的恶性肿瘤患者118例,测量其化疗前后的S-TK1水平。结果 118例恶性肿瘤患者化疗后STK1水平为(1.58±1.32)pmol·L-1,低于化疗前的(1.84±1.40)pmol·L-1,但差异无统计学意义(P>0.05);化疗后S-TK1阳性率为18.64%,低于化疗前的30.51%,差异有统计学意义(P<0.05)。S-TK1水平与患者年龄、性别、部位、TNM分期、化疗方案、既往治疗史、检测时间无关。结论 S-TK1对恶性肿瘤的治疗效果评估有重要的参考价值,但其影响因素尚有待进一步研究。

Objective To explore the clinical significance of the changes of serum thymidine kinase-1 （S-TK1） level in the patients with malignant tumor before and after chemotherapy. Methods The 118 patients with malignant tumor were collected, the S-TK1 levels of these patients were detected before and after chemotherapy. Results The S-TK1 level in the 118 patients with malignant tumor patients after chemotherapy [ （1.58± 1.32） pmol·L- 1 ] was lower than that before chemotherapy [ （ 1.84 ±1.40） pmol · L-1 ], but there was no statistical significance （P 〉0.05）. The S-TK1 positive rate in the 118 patients with malignant tumor patients after chemotherapy （ 18.64% ） was lower than that before chemotherapy （30.51%） ,there was the statistical significance （P 〈0.05 ）. The S-TK1 level was not related with age, gender, tumor position, TNM staging, chemotherapy regimen, previous medical history, detection time （ P 〉 0.05 ）. Conclusion The S-TK1 level is an important mark for estimating treatment result, the influencing factors need further study.